Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R. Saad F, et al. Among authors: takahashi s. Ann Oncol. 2012 May;23(5):1341-1347. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10. Ann Oncol. 2012. PMID: 21986094 Free article.
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome T, Terui Y, Hatake K. Kodaira M, et al. Among authors: takahashi s. Ann Oncol. 2010 Jun;21(6):1163-1167. doi: 10.1093/annonc/mdp583. Epub 2009 Dec 17. Ann Oncol. 2010. PMID: 20019088 Free article.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K. Ennishi D, et al. Among authors: takahashi s. Ann Oncol. 2008 Nov;19(11):1921-6. doi: 10.1093/annonc/mdn392. Epub 2008 Jun 23. Ann Oncol. 2008. PMID: 18573805 Free article.
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K. Kodaira M, et al. Among authors: takahashi s. Ann Oncol. 2010 Jul;21(7):1563-1565. doi: 10.1093/annonc/mdq299. Ann Oncol. 2010. PMID: 20573851 Free article. No abstract available.
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Tanizaki J, et al. Among authors: takahashi s. Ann Oncol. 2022 Feb;33(2):216-226. doi: 10.1016/j.annonc.2021.11.009. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34843940 Free article. Clinical Trial.
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T. Tahara M, et al. Among authors: takahashi s. Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040. Ann Oncol. 2018. PMID: 29408977 Free article. Clinical Trial.
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C. Yamada Y, et al. Among authors: takahashi s. Ann Oncol. 2018 Mar 1;29(3):624-631. doi: 10.1093/annonc/mdx816. Ann Oncol. 2018. PMID: 29293874 Free PMC article. Clinical Trial.
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. Kamijima T, et al. Among authors: takahashi s. Anticancer Res. 2022 Jun;42(6):3099-3108. doi: 10.21873/anticanres.15798. Anticancer Res. 2022. PMID: 35641302
11,148 results
You have reached the last available page of results. Please see the User Guide for more information.